The conventional wisdom about Silicon Valley is that it’s a playground for the underdogs, a fertile ground for young entrepreneurs building startups that are going to “change the world.”
Instead, the Bay Area—while, yes, still home to thirsty young entrepreneurs—is increasingly... Read more »
For the second time in two months, remarkable recoveries from desperate cases of cancer have led to early approval of a cutting-edge therapy called CAR-T, which is made from a patient’s own genetically engineered cells.
More than a month before the... Read more »
[Updated at 1:05 p.m. on 10/17/2017 to add comments from Duo CEO Dug Song; see below.] Ann Arbor, MI-based cybersecurity startup Duo Security today announced that it has closed on a Series D financing round valued at $70 million,... Read more »
True artificial intelligence is likely decades away, if it ever comes. In the meantime, companies are making robots “smarter” in less dramatic ways that nevertheless could prove quite useful.
Veo Robotics is one of the players trying to boost the intelligence... Read more »
In advance of an anticipated Senate hearing on drug prices, President Donald Trump once again denounced drug companies as “getting away with murder.” The first time he did so, using the same phrase just before his inauguration, the markets shuddered.... Read more »
Entrepreneur-turned-venture capitalist Vinod Khosla made big headlines almost six years ago when he wrote a blog post called “Do We Need Doctors or Algorithms?” In it, he said medicine needed to be reinvented and he predicted a new era in which... Read more »
What began as a kind of business experiment in innovation has acquired a life of its own.
The idea in 2011 was to create a space at what was then Johnson & Johnson’s pharmaceutical research and development facility in San Diego... Read more »
In a year of tragedies across the U.S., natural or otherwise, it seemed this week was California’s turn. Fueled by high winds, low humidity, and ample dry vegetation, fires swept through several towns across the state and, as of this writing,... Read more »
An experimental Spark Therapeutics gene therapy intended to treat rare eye diseases that lead to blindness has won the unanimous backing of an advisory panel to the FDA.
Following a daylong hearing that included presentations from Philadelphia-based Spark (NASDAQ: ONCE),... Read more »
Merck is pulling the plug on a cholesterol-lowering drug that met its main goal in a clinical trial but still raised questions about whether it would benefit patients.
Kenilworth, NJ-based Merck (NYSE: MRK) said Wednesday that it won’t seek regulatory... Read more »
Within 20 years, computer keyboards will be relegated to the technology dustbin, says Android co-founder Rich Miner.
Miner helped shape the smartphone era with Android, a mobile operating system startup that Google acquired in 2005. Android software now powers over... Read more »
In the run-up to a key vote on an experimental gene therapy, the FDA raised no major flags about the drug’s track record but said its long-term effect remains an open question.
That question should receive a thorough airing Thursday, when... Read more »
KalVista Pharmaceuticals has inked a partnership with pharmaceutical giant Merck for its lead drug, an experimental treatment for a complication of diabetes that can lead to blindness.
According to the deal announced Tuesday, Merck (NYSE: MRK) will pay Cambridge, MA-based... Read more »